The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The approval of the first malaria treatment for newborns and young infants could lead to imminent widespread use in Africa, drugmaker Novartis said Tuesday. The drug, known as Coartem Baby or Riamet ...

(RTTNews) - Novartis Pharma AG, affiliated to Swiss drug major Novartis AG (NVS), announced Tuesday that Coartem (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria ...

Novartis (NVS) Friday announced that the World Health Organization has prequalified Coartem® (artemether-lumefantrine) Baby, the first and only antimalarial developed specifically for newborns and ...

WHO prequalification of Coartem Baby means newborns can be safely treated rather than using medication for older children The first malaria treatment for babies has been approved by the World Health ...

Basel, April 24, 2026 - Novartis today announced that the World Health Organization (WHO) has prequalified Coartem® (artemether-lumefantrine) Baby, the first and only antimalarial developed ...

Add Yahoo as a preferred source to see more of our stories on Google. Coartem Baby already has approval in the West African nation of Ghana and drugmaker Novartis said it now expects eight African ...